ELUTIA INC.
ELUTIA INC. (ELUT): 3 pipeline candidates · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.2 months
D/E 1.45
Lead: Approved
3 candidates
N/A
4 buys · 0 sells (180d)
A transparent, data-derived signal for ELUTIA INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$42.8M
Cash
$28.5M
Quarterly Burn
$7.8M
Runway
13.2 mo
Revenue
$3.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Frequently asked questions
How many drug candidates are in ELUTIA INC.'s pipeline?
ELUTIA INC. (ELUT) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ELUTIA INC.'s lead drug candidate?
ELUTIA INC.'s most advanced tracked candidate is elupro (Approved) for Mitigate complications associated with the implantation of electronic medical devices such as pacemakers, internal defibrillators and neurostimulation devices.
What is ELUTIA INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ELUTIA INC. has approximately 13.2 months of cash runway.
What is ELUTIA INC.'s market capitalization?
ELUTIA INC.'s market capitalization is approximately $42.8M.
Who is the CEO of ELUTIA INC.?
Dr. C. Randal Mills Ph.D. is the chief executive officer of ELUTIA INC. (ELUT).
Get the full picture on ELUTIA INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.